---
title: Wearable cues reduce daily freezing
nct_id: NCT06416345
phase: NA
status: RECRUITING
sponsor: Amsterdam UMC, location VUmc
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06416345"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06416345"
last_fetched: "2026-05-10T14:02:10.116Z"
source: "Parkinson's Pathways (curated)"
---
# Wearable cues reduce daily freezing

**Goal (in five words):** Wearable cues reduce daily freezing

**Official Title:** Cue2Walk, Cost-effectiveness of Automated Freezing Detection and Provision of External Cues in Comparison to Usual Care in People With Parkinson's Disease

**Trial ID:** [NCT06416345](https://clinicaltrials.gov/study/NCT06416345)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Amsterdam UMC, location VUmc
- **Target Enrollment:** 84 participants
- **Start Date:** 2025-08-22
- **Completion Date:** 2027-12-01
- **Conditions:** Parkinson Disease
- **Interventions:** Cue2Walk, Usual Care
- **Intervention Types:** DEVICE, OTHER

## Summary For Families

The goal is to reduce daily freezing of gait and see if an automated cueing system is more effective and cost efficient than usual care. Cue2Walk is a wearable system that automatically detects freezing episodes and delivers timed external cues, like rhythmic sounds or vibrations, to help restart and regularize stepping; it is meant to work alongside your current treatments and does not replace levodopa or DBS. The trial seeks people with Parkinson's diagnosed by UK Brain Bank criteria who have daily freezing, are Hoehn and Yahr stage 2 to 4, have stable medication or DBS settings, and can walk five minutes unassisted. People who already use a personal cueing device, have had prior Cue2Walk use, are in another study, or have cognitive impairment preventing understanding instructions (MoCA score under 16) are excluded.

## Eligibility

- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of Parkinson's disease according to UK Brain bank criteria
* Daily Freezing of Gait
* Hoehn-Yahr stage 2-4
* Stable medication regime and/or DBS settings as determined by the treating neurologist
* Ability to walk 5 minutes while unassisted by another person

Exclusion Criteria:

* Participation in another clinical study
* Use of a personal cueing device at home
* Previous use of the Cue2Walk medical device
* Presence of co-morbidities that would hamper participation
* Cognitive impairment preventing understanding of therapeutic instructions (Montreal Cognitive Assessment (MoCA) Score \<16)
```

## Locations (2)

- Radboudumc, Nijmegen, Gelderland, Netherlands _(51.8425, 5.8528)_
  - Jorik Nonnekes, MD, PhD — (CONTACT) — Jorik.Nonnekes@radboudumc.nl
  - Jorik Nonnekes, MD, PhD — (PRINCIPAL_INVESTIGATOR)
  - Lotte van de Venis, PhD — (SUB_INVESTIGATOR)
- Amsterdam UMC, location VUmc, Amsterdam, North Holland, Netherlands _(52.3740, 4.8897)_
  - Erwin EH van Wegen, Dr. — (CONTACT) — 020-4440461 — e.vanwegen@amsterdamumc.nl
  - Erwin EH van Wegen, PhD — (PRINCIPAL_INVESTIGATOR)
  - Matthijs van der Laan, MSc — (SUB_INVESTIGATOR)
  - Marc B. Rietberg, PhD — (SUB_INVESTIGATOR)
  - Vincent de Groot, Prof. dr. — (SUB_INVESTIGATOR)

## Central Contacts

- Erwin EH van Wegen, PhD — (CONTACT) — 020-4440461 — e.vanwegen@amsterdamumc.nl

---

*Canonical: https://parkinsonspathways.com/trial/NCT06416345*  
*HTML version: https://parkinsonspathways.com/trial/NCT06416345*  
*Source data: https://clinicaltrials.gov/study/NCT06416345*